Teklu Alula M, Tsegaye Eyuel, Fekade Daniel, Hailemelak Abraham, Weiss William, Hassen Elham, Simmons Nicole, Zewdu Solomon, Berhan Yifru, Getachew Assefa, Hagos Tesfalem, Alebachew Achamyeleh, Damena Melake, Sitotaw Yohannes, Assefa Yibeltal, Medhin Girmay, Ruff Andrea
ACM Project Implementation Office (ACM), Addis Ababa, Ethiopia.
Addis Ababa University, Faculty of Medicine, Addis Ababa, Ethiopia.
Ethiop J Health Sci. 2017 Feb;27(Suppl 1):3-16. doi: 10.4314/ejhs.v27i1.2s.
The purpose of this paper is to describe the establishment of the Advanced Clinical Monitoring of ART Project in Ethiopia for monitoring and evaluation of the longitudinal effectiveness of the ART program and to show the opportunities it presents. This cohort was established in response to the 2005 call by WHO for establishing additional mechanisms for stronger monitoring of ART and the need for creating the platform to generate evidence to guide the care given for the ever increasing number of patients on ART in Ethiopia.
A participatory and multi-stage process which started from a consensus building workshop and steered by a mother protocol as well as guiding documents which dictated the degree of engagement and expectations was followed. The primary and secondary aims of the study were agreed upon. A multi-site longitudinal observational clinical cohort was established by a consortium of stakeholders including seven Ethiopian medical schools and their affiliated referral hospitals, John Hopkins University, Ethiopian Public Health Institute, Ministry of Science and Technology, US Centers for Disease Prevention and Control - CDC-Ethiopia, and the Federal Ministry of Health. Adult and adolescent cohorts covering the age range of 14+ years) and pediatric cohorts covering those below age 14 years were the two main cohorts. During the initial recruitment of these cohorts information was extracted from existing documents for a total of 2,100 adult participants. In parallel, a prospective cohort of 1,400 adult and adolescent patients were enrolled for ART initiation and follow-up. Using similar recruitment procedures, a total of 120 children were enrolled in each of retrospective and prospective cohorts. Replacement of participants were made in subsequent years based on lost follow up and death rates to maintain adequacy of the sample to be followed-up.
Between January 2005 and August 2013 a total of 4,339 patients were followed for a median of 41.6 months and data on demographic characteristics, baseline and ongoing clinical features, hospitalization history, medication and laboratory information were collected. 39,762 aliquots and 25,515 specimens of plasma and dryblood-spots respectively were obtained and stored longitudinally from October 2009 to August 2013. The project created a research platform for researchers, policy and decision makers. Moreover, it encouraged local and international investigators to identify and answer clinically and programmatically relevant research questions using the available data and specimens. Calls for concept notes paired with multiple trainings to stimulate investigators to conduct analyses further boosted the potential for doing research.
A comprehensive and resourceful mechanism for scientific inquiry was established to support the national HIV/ART program. With meaningful involvement and defined roles, establishment of a study, which involved multiple institutions and investigators, was possible. Since ACM is the largest multi-site clinical cohort of patients on antiretroviral treatment in Ethiopia-which can be used for research and for improving clinical management-considering options to sustain the project is crucial.
本文旨在描述埃塞俄比亚抗逆转录病毒治疗高级临床监测项目的建立,以监测和评估抗逆转录病毒治疗项目的长期效果,并展示该项目带来的机遇。该队列的建立是为了响应世界卫生组织2005年的呼吁,即建立更多机制以加强对抗逆转录病毒治疗的监测,以及创建一个平台来生成证据,以指导埃塞俄比亚越来越多接受抗逆转录病毒治疗患者的护理。
采用了一个参与性的多阶段过程,该过程始于一个共识构建研讨会,并由一个总方案以及规定参与程度和期望的指导文件进行指导。确定了研究的主要和次要目标。由包括七所埃塞俄比亚医学院及其附属转诊医院、约翰霍普金斯大学、埃塞俄比亚公共卫生研究所、科学技术部、美国疾病预防控制中心 - 埃塞俄比亚分部以及联邦卫生部在内的利益相关者联盟建立了一个多地点纵向观察性临床队列。两个主要队列分别是年龄在14岁及以上的成人和青少年队列以及14岁以下的儿童队列。在这些队列的初始招募期间,从现有文件中提取了总共2100名成年参与者的信息。与此同时,招募了1400名成年和青少年患者作为前瞻性队列开始接受抗逆转录病毒治疗并进行随访。使用类似的招募程序,回顾性和前瞻性队列各招募了120名儿童。在随后的几年中,根据失访率和死亡率对参与者进行替换,以保持随访样本的充足性。
在2005年1月至2013年8月期间,共对4339名患者进行了中位时间为41.6个月的随访,并收集了有关人口统计学特征、基线和持续临床特征、住院病史、用药和实验室信息的数据。从2009年10月至2013年8月,分别纵向获取并储存了39762份血浆样本和25515份干血斑样本。该项目为研究人员、政策制定者和决策者创建了一个研究平台。此外,它鼓励国内外研究人员利用现有数据和样本确定并回答临床和项目相关的研究问题。征集概念说明并开展多次培训以激励研究人员进行分析,进一步提升了开展研究的潜力。
建立了一个全面且资源丰富的科学探究机制,以支持国家艾滋病毒/抗逆转录病毒治疗项目。通过有意义的参与和明确的角色,涉及多个机构和研究人员的研究得以建立。由于ACM是埃塞俄比亚最大的接受抗逆转录病毒治疗患者的多地点临床队列,可用于研究和改善临床管理,因此考虑维持该项目的选项至关重要。